A Pfizer vaccine to protect older adults and infants from respiratory syncytial virus (RSV) infection has shown what some scientists are calling exciting promise in late-stage trials.
In one company Read More
Read" />
Bringing you the latest updates
A Pfizer vaccine to protect older adults and infants from respiratory syncytial virus (RSV) infection has shown what some scientists are calling exciting promise in late-stage trials.
In one company Read More